Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
― | ― | ― | ― | ― | Gross Profit |
16.34M | 19.95M | 48.21M | ― | ― | EBIT |
-139.62M | -120.43M | -75.21M | -106.02M | -97.94M | EBITDA |
-126.86M | -111.87M | -67.88M | -99.37M | -93.19M | Net Income Common Stockholders |
-138.49M | -119.69M | -75.08M | -105.31M | -94.43M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
― | ― | ― | ― | ― | Total Assets |
177.77M | 240.75M | 278.11M | 221.57M | 184.39M | Total Debt |
104.78M | 40.32M | 26.42M | 25.10M | 23.49M | Net Debt |
25.49M | -131.57M | -186.51M | -145.96M | -104.29M | Total Liabilities |
125.92M | 69.97M | 62.02M | 54.83M | 50.05M | Stockholders Equity |
― | ― | ― | ― | ― |
Cash Flow | Free Cash Flow | |||
-126.22M | -121.82M | -56.14M | -92.62M | -101.18M | Operating Cash Flow |
-121.65M | -115.95M | -50.68M | -89.10M | -85.01M | Investing Cash Flow |
― | ― | ― | ― | ― | Financing Cash Flow |
― | ― | ― | ― | ― |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $4.19B | ― | -58.66% | ― | 42.77% | -51.27% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
50 Neutral | $256.78M | ― | -31.16% | ― | ― | 15.14% | |
43 Neutral | $72.97M | ― | -273.36% | ― | 883.05% | 62.93% | |
39 Underperform | $30.94M | ― | -102.99% | ― | ― | 30.37% | |
34 Underperform | $16.63M | ― | -208.72% | ― | ― | 56.38% | |
24 Underperform | $118.00 | ― | -267.30% | ― | -81.66% | 11.95% |
Gritstone bio, Inc., a biotechnology company, has filed for Chapter 11 bankruptcy and conducted an auction of its assets. Hercules Capital, Inc., Future Solutions Investments LLC, and Seattle Project Corp. emerged as successful bidders for the company’s machinery, intellectual property, and other assets, respectively, totaling approximately $21.25 million in cash proceeds, pending court approval.
More about Gritstone bio
YTD Price Performance: -99.41%
Average Trading Volume: 18,650,820
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.48M
Gritstone bio, Inc. has filed for Chapter 11 bankruptcy, highlighting the speculative nature of trading its stock during this period. Investors are cautioned as the company’s monthly operating report, though submitted to comply with legal requirements, is not a reliable indicator of future performance or investment decisions. The report reveals significant financial challenges, with no assurance on recovery prospects for stakeholders.